FYI

Extended-Release Naltrexone

Vivitrol (naltrexone for extended-release injectable suspension) is indicated for oncemonthly treatment of alcohol dependence in patients who are able to abstain from drinking in an outpatient setting and are not actively drinking when initiating treatment. For more information, contact Cephalon Inc. by visiting www.vivitrol. com or by calling 800-896-5855.

Terminal Estimates Payment Due

The MedCom Terminal System helps clarify a patient's maximum financial responsibility for an office visit. The system has access to more than 300 payers and plans. For more information, contact MedCom USA Inc. by visiting www.medcomusa.com or by calling 800-327-6537, extension 620.

Healthy Mental Aging

The Geriatric Mental Health Foundation's new publication, "Healthy Aging: Keeping Mentally Fit as You Age" advises older adults on ways they can keep their minds healthy. For more information, visit www.gmhfonline.org/gmhf/consumer/ factsheets/hlthage_mental.html.

Hurricane Counseling Grants Awarded

The Substance Abuse and Mental Health Services Administration and the Federal Emergency Management Agency have awarded \$1.6 million for crisis counseling

INDEX OF ADVERTISERS

AstraZeneca Pharmaceuticals LP.	
Corporate	21
Seroquel	65-66
Bristol-Myers Squibb Company	
Emsam	18a-18f, 19
Bristol-Myers Squibb Company and Otsu Pharmaceutical, Inc.	
Abilfy	42a-42h
Cephalon, Inc.	
Provigil	9-10
Corporate	23
Vivitrol	33-34
Forest Pharmaceuticals, Inc.	
Campral	10a-10b
Lexapro	50a-50b
Namenda	59-62
Janssen Pharmaceutica Products, L.P.	
RisperdalConsta	29-32
Risperdal	69-72
Corporate	79
loss Dharmacauticala Inc	
Jazz Pharmaceuticals, Inc. Xyrem	45-49
	رب رب
JDS Pharmaceuticals, LLC	
PEXEVA	25-26
Eli Lilly and Company	
Zyprexa	3-6
Corporate	37
Cymbalta	75-76
Pfizer Inc.	
Corporate	15, 39, 53
Geodon	55-56, 83-84
Qwest	
Corporate	81
Shire US Inc.	
Corporate Adderall XR	17 41-42
State Farm	
Insurance	27
Takeda Pharmaceuticals North America	, Inc.
Rozerem	12-14

34a-34d, 66a-66d

Wyeth Pharmaceuticals Inc.

assistance in the aftermath of hurricanes Katrina, Rita, and Wilma. For more information, visit www.samhsa.gov/news/ newsreleases/060419_alabama.htm.

Web Site Consolidates Flu Info

The Department of Health and Human Services has launched a Web site to provide one-stop access to U.S. government information on avian and pandemic flu. Visitors can access up-to-date response plans and learn about current tests, vaccines, and medications. For more information, visit www.pandemicflu.gov.

UPCOMING MEETING COVERAGE

American Psychiatric Association American Society of Addiction Medicine NIMH: New Clinical Drug Evaluation Unit University of Arizona: Annual Santa Fe Psychiatric Symposium



BRIEF SUMMARY. See package insert for full prescribing information

BRIEF SUMMARY. See package insert for full prescription mormation.

Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with adjustance of the properties of the propert either cardiovascular (e.g., heart failure, sudden death) or infectious oved for the treatment of patients with Dementia-Related Psychosis.

4.5%, compared in an rise of about 2.5% in the placided group. Although the causies of death were orient, fined of the deaths appeared to the either cardiovated (2.6), bear tallaws, or the cardiovate of the place of the cardiovate of the cardiova OSE III Education with Ose Company State Continuation of the State Country of the Country of the

information and instructions in the Polisite Anternation Outcome and Company a pnotophobia; Rare: eye hemorrhage, visual field defect, keratitis, keratoconjunctivitis. <u>Urogenital System</u>—Infrequent: Impotence, abnormal ejaculation, amenormba, hematuria, menorrhagia, female lactation, polyuria, urlinary retention, metrorrhagia, male sexual dysfunction, anorgasmia, glycosuria; Rare gynecomastia, vaginal hemorrhage, nocturia, oligiuria, female sexual dysfunction, uterine hemorrhage.

Adverse Finding Observed in Trials of Intramuscular GED00N: In these studies, the most commonly observed adverse events associated with the use of intramuscular GED00N (proup were headache (13%), nausea (12%), and somnolence (20%). Adverse Events at an Incidence >1% in Short-Term Fixed-Dose Intramuscular Trials: The following list enumerates the treatment-emergent adverse events that occurred in >1% of GED00N (patients (in the higher dose groups) and at laset twice that of the lowest intramuscular GED00N group.

Body as a Whole—headache, injection site pain, asthenia, abdominal pain, flu syndrome, back pain. Cardiovascular—postural hypotension, hypertension, bradycardia, vasodilation. <u>Digestive</u>—nausea, rectal hemorrhage, diarrhe, vomiting, dyspepsia, anorexia, constipation, tooth disorder, dry mouth. <u>Bervous</u>—dizenses, anxiety, insomnia, somnolence, akathisia, agitation, extrapyramidal syndrome, hypertonia, cogwheel rigidity, paresthesia, personality disorder, psychosis, speech disorder. <u>Respiratory</u>—thinitis. Skin and Appendages—furunculosis, sweating. <u>Urogenital</u>—dysmenorrhea, praipsim. **DRIG ABUSE AND DEPENDENCE**—controlled substance. **OVERDOSAGE**—In premarketing trials in over 5400 patients, accidental or intentional overdosage of GED00N was documented in 10 patients. All patients survived without sequelae. In the patient taking the largest confirmed amount (3240 mg), the only symptoms reported were minimal seadation, sturring of speech, and transitory hypertension (BP 20075).

Revised May 2005

March 2008

March 20